Pharmaceutic phase, 24–25, 25t
Pharmacodynamics
overview, 33–34
receptor theory, 34–35
Pharmacokinetics
active diffusion, 26
overview, 26
passive diffusion, 26
pinocytosis, 26
Pharmacology
antimicrobials.SeeAntimicrobials
cardiac circulatory medications. SeeCardiac
circulatory medications
dose calculations. SeeDose calculations
drug action and drug interactions. SeeDrug action
and drug interactions
endocrine medications. SeeEndocrine medications
eye and ear disorders. SeeEye and ear disorders
fluid and electrolyte therapy. SeeFluid and
electrolyte therapy
gastrointestinal system. SeeGastrointestinal system
herbal therapy. SeeHerbal therapy
immunologic agents. SeeImmunologic agents
inflammation.SeeInflammation
narcotic agonists. SeeNarcotic agonists
nervous system drugs. SeeNervous system drugs
nursing process. SeeNursing process and
pharmacology
nutritional support therapies. SeeNutritional support
therapies
overview of. SeeBasics of pharmacology
principles of medication administration. See
Administration, medication
respiratory diseases. SeeRespiratory diseases
skin disorders. SeeSkin disorders
substance abuse and. SeeSubstance abuse
vitamins and minerals. SeeVitamins and minerals
Pharyngitis, 260
Phase I trials: initial pharmacological evaluation, 9
Phase II trials: limited controlled evaluation, 10
Phase III trials: extended clinical evaluation, 10–11
category A, 10
category B, 10
category C, 10
category D, 11
category X, 11
Phenelzine (Nardil), 301
Phenindione
contraindicated with breastfeeding, 55
Phenobarbital, 275, 294
interaction with chloramphenicol, 236
Phenolphthalein, 339
Phenothiazines, 258, 296–297, 333
anxiolytics, 296–297
Phentolamine (Regitine), 285
Phenytoin, 294
interaction with chloramphenicol, 236
pH level, 28
Phosphorus, 177–180
hyperphosphatemia, 178–179
hypophosphatemia, 179–180
Phrazinamide, 243t
Physician or advanced practice intervention, 50
Physostigmine, 404t
Pilocarpine, 287, 404t
Pinocytosis, 26
Pioglitazone (Actos), 396
Piperacillin (Pipracil), 213t
Piperacillin and tazobactam (Zosyn, Tazocin), 213t
Piperazine (Antepar, Vermizine), 250, 297t
Piperidine, 297t
Pituitary gland, 387
Placebo effect, 38
Plasma protein level, 30
Pneumonia, 261
Polycarbonphil (FiberCon), 339
Polyethylene glycol (PEG), 338
Polymyxins, 407t
interaction with aminoglycosides, 230
interaction with vancomycin, 228
Polythiazide (Renese), 360
Poplypharmacy, 56
Postexposure HIV prophylaxis, 320, 320t
Potassium, 164–168
hyperkalemia, 164–165
hypokalemia, 165–168
supplements, 167t
Potassium-sparing diuretics, 361, 363–364
interaction with penicillin, 214
Potentiation, 37
Povidone-iodine (Betadine), 381
Pravastatin (Pravachol), 368
Praziquantel (Biltricide), 250
Prazosin (Minipress), 369(^452) Index